Assignee
GANYMED PHARMACEUTICALS AG
DE·35 granted patents·8 pending applications·241 citations·filing 2000–2019
Top patents by PatentIndex Score
43 records- 0198US7527933B2Genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2003·Granted May 5, 2009·115 cites·5 claims
- 0294US9751934B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Sep 5, 2017·13 cites·20 claims
- 0391US10813996B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Oct 27, 2020·4 cites·18 claims
- 0491US7785801B2Identification of surface-associated antigens for tumor diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2005·Granted Aug 31, 2010·14 cites·4 claims
- 0590US10233253B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Mar 19, 2019·7 cites·16 claims
- 0690US9770487B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinomaGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Sep 26, 2017·11 cites·30 claims
- 0789US10053512B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Aug 21, 2018·6 cites·34 claims
- 0889US9512232B2Antibodies against Claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Dec 6, 2016·9 cites·11 claims
- 0988US10314890B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Jun 11, 2019·5 cites·40 claims
- 1087US10738108B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Aug 11, 2020·2 cites·28 claims
- 1187US10137195B2Therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Nov 27, 2018·7 cites·19 claims
- 1285US10174104B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Jan 8, 2019·3 cites·24 claims
- 1385US9775785B2Antibody to genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Oct 3, 2017·5 cites·12 claims
- 1484US11473085B2Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2019·Granted Oct 18, 2022·1 cites·10 claims
- 1584US9475867B2Monoclonal antibodies for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Oct 25, 2016·3 cites·18 claims
- 1684US8354104B2Monoclonal antibodies for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2008·Granted Jan 15, 2013·3 cites·5 claims
- 1783US9433675B2Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Sep 6, 2016·5 cites·23 claims
- 1881US7326767B1Immunotherapeutic methods using epitopes of WT-1 and GATA-1GANYMED PHARMACEUTICALS AG·Filed 2000·Granted Feb 5, 2008·16 cites·4 claims
- 1980US8961980B2Monoclonal antibodies for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2012·Granted Feb 24, 2015·5 cites·23 claims
- 2079US10022444B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Jul 17, 2018·2 cites·32 claims
- 2177US9902778B2Cancer therapy using CLDN6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Feb 27, 2018·1 cites·19 claims
- 2275US9932401B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Apr 3, 2018·1 cites·19 claims
- 2374US7875424B2Identification of tumour-associated cell surface antigens for diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2004·Granted Jan 25, 2011·1 cites·1 claims
- 2470US11976130B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2018·Granted May 7, 2024·0 cites·16 claims
- 2570US7429461B2Genetic products differentially expressed in tumors and use thereofGANYMED PHARMACEUTICALS AG·Filed 2003·Granted Sep 30, 2008·2 cites·7 claims
- 2668US10919974B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Feb 16, 2021·0 cites·12 claims
- 2766US10745477B2Antibodies specific for claudin 6 (CLDN6)GANYMED PHARMACEUTICALS AG·Filed 2018·Granted Aug 18, 2020·0 cites·19 claims
- 2866US9453260B2Genetic products differentially expressed in tumors and use thereofGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Sep 27, 2016·0 cites·8 claims
- 2965US10414824B2Genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Sep 17, 2019·0 cites·11 claims
- 3064US10844133B2Cancer therapy using CLDN6 target-directed antibodies in vivoGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Nov 24, 2020·0 cites·20 claims
- 3164US10125196B2Monoclonal antibodies for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Nov 13, 2018·0 cites·12 claims
- 3263US10036753B2Identification of surface-associated antigens for tumor diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Jul 31, 2018·0 cites·14 claims
- 3363US2011135640A1Identification of tumour-associated cell surface antigens for diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2010·Application pending·0 cites
- 3462US2017101479A1Genetic products differentially expressed in tumors and use thereofGANYMED PHARMACEUTICALS AG·Filed 2016·Application pending·0 cites
- 3559US9733251B2Identification of tumour-associated cell surface antigens for diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Aug 15, 2017·0 cites·11 claims
- 3657US9919036B2Identification of tumor-associated antigens for diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Mar 20, 2018·0 cites·21 claims
- 3757US2017240646A1Genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 3856US2018119146A1Methods and compositions for diagnosis and treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 3955US2016193335A1Identification of Surface-Associated Antigens for Tumor Diagnosis and TherapyGANYMED PHARMACEUTICALS AG·Filed 2016·Application pending·0 cites
- 4053US2014199762A1Immunotherapeutic Methods Using Epitopes of WT-1 and GATA-1GANYMED PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 4149US2015132253A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 4248US2018258180A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Application pending·0 cites
- 4346US10596256B2Monoclonal anti-GT 468 antibodies for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Mar 24, 2020·0 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when GANYMED PHARMACEUTICALS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →